Home / Companies / Neumora Therapeutics, Inc. / 28 May 2025
Neumora Therapeutics, Inc.: meeting of 28 May 2025
Votes reported on Form N-PX, item by item
59 Form N-PX filers reported votes at the Neumora Therapeutics, Inc. meeting of 28 May 2025. Their records fall into 4 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
2 nominees; 43.9% of reported votes for; 42 filers withheld from or voted against at least one nominee.
186 vote records from 59 filers. 20 of the 59 filers that marked the item either way voted against management.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
93 vote records from 59 filers. 0 of the 59 filers that marked the item either way voted against management.
CAPITAL STRUCTUREIssuer
CAPITAL STRUCTURE: management items
Management items in this category are shown together; filers word and number them differently.
99 vote records from 59 filers. 1 of the 59 filers that marked the item either way voted against management.
COMPENSATIONIssuer
COMPENSATION: management items
Management items in this category are shown together; filers word and number them differently.
87 vote records from 56 filers. 52 of the 56 filers that marked the item either way voted against management.
How the largest families voted
| Family | 1. Directors | 2. Auditor |
|---|---|---|
| Vanguard | For | For |
| BlackRock and iShares | Split or no vote | For |
| Fidelity | Split or no vote | For |
| Dimensional | Abstain or withhold * | For |
| State Street and SPDR | For | For |
| Invesco | Split or no vote | For |
| Equitable | Abstain or withhold * | For |
| Charles Schwab | For | For |
| Nuveen and TIAA | Split or no vote | For |
| ProShares and ProFunds | Abstain or withhold * | For |
| John Hancock and Manulife | Abstain or withhold * | For |
| Morgan Stanley, Eaton Vance and Calvert | Abstain or withhold * | For |
| J.P. Morgan | For | For |
| Goldman Sachs | Abstain or withhold * | For |
| Northern Trust and FlexShares | Split or no vote | For |
| SEI | Split or no vote | For |
| T. Rowe Price | Split or no vote | For |
| Lincoln Financial | For | For |
| Voya | Split or no vote | For |
| Nationwide | Abstain or withhold * | For |
| Victory Capital | Abstain or withhold * | For |
| Guggenheim and Rydex | Abstain or withhold * | For |
| Columbia Threadneedle | For | For |
| Pacific Life funds | Split or no vote | For |
| Global X | Split or no vote | For |
| Federated Hermes | Abstain or withhold * | For |
| DWS | Abstain or withhold * | For |
| MassMutual | Split or no vote | For |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Neumora Therapeutics, Inc. meeting?
59 Form N-PX filers reported votes at the meeting of 28 May 2025. The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Neumora Therapeutics, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Neumora Therapeutics, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Neumora Therapeutics, Inc. with a meeting date within three days of 28 May 2025. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.